These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 19499915)

  • 21. Hyaluronic acid-nimesulide conjugates as anticancer drugs against CD44-overexpressing HT-29 colorectal cancer in vitro and in vivo.
    Jian YS; Chen CW; Lin CA; Yu HP; Lin HY; Liao MY; Wu SH; Lin YF; Lai PS
    Int J Nanomedicine; 2017; 12():2315-2333. PubMed ID: 28392690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone.
    Ito T; Fraser IP; Yeo Y; Highley CB; Bellas E; Kohane DS
    Biomaterials; 2007 Apr; 28(10):1778-86. PubMed ID: 17204321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: an alternative to prodrug approach.
    Oommen OP; Garousi J; Sloff M; Varghese OP
    Macromol Biosci; 2014 Mar; 14(3):327-33. PubMed ID: 24130147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hybrid hyaluronan hydrogel encapsulating nanogel as a protein nanocarrier: new system for sustained delivery of protein with a chaperone-like function.
    Hirakura T; Yasugi K; Nemoto T; Sato M; Shimoboji T; Aso Y; Morimoto N; Akiyoshi K
    J Control Release; 2010 Mar; 142(3):483-9. PubMed ID: 19951730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment.
    Hyung W; Ko H; Park J; Lim E; Park SB; Park YJ; Yoon HG; Suh JS; Haam S; Huh YM
    Biotechnol Bioeng; 2008 Feb; 99(2):442-54. PubMed ID: 17625788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
    Afify A; Purnell P; Nguyen L
    Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Light-activatable prodrugs based on hyaluronic acid biomaterials.
    Ossipov DA; Romero AB; Ossipova E
    Carbohydr Polym; 2018 Jan; 180():145-155. PubMed ID: 29103490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
    Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
    Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide.
    Yeo Y; Adil M; Bellas E; Astashkina A; Chaudhary N; Kohane DS
    J Control Release; 2007 Jul; 120(3):178-85. PubMed ID: 17582645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells.
    Hornof M; de la Fuente M; Hallikainen M; Tammi RH; Urtti A
    J Gene Med; 2008 Jan; 10(1):70-80. PubMed ID: 18044795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor.
    Dufaÿ Wojcicki A; Hillaireau H; Nascimento TL; Arpicco S; Taverna M; Ribes S; Bourge M; Nicolas V; Bochot A; Vauthier C; Tsapis N; Fattal E
    J Control Release; 2012 Sep; 162(3):545-52. PubMed ID: 22820451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis by AGET ATRP of degradable nanogel precursors for in situ formation of nanostructured hyaluronic acid hydrogel.
    Bencherif SA; Washburn NR; Matyjaszewski K
    Biomacromolecules; 2009 Sep; 10(9):2499-507. PubMed ID: 19711888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corneal endothelial hyaluronidase: a role in anterior chamber hyaluronic acid catabolism.
    Schwartz DM; Jumper MD; Lui GM; Dang S; Schuster S; Stern R
    Cornea; 1997 Mar; 16(2):188-91. PubMed ID: 9071532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanostructured hyaluronic acid-based materials for active delivery to cancer.
    Ossipov DA
    Expert Opin Drug Deliv; 2010 Jun; 7(6):681-703. PubMed ID: 20367530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles.
    Mizrahy S; Goldsmith M; Leviatan-Ben-Arye S; Kisin-Finfer E; Redy O; Srinivasan S; Shabat D; Godin B; Peer D
    Nanoscale; 2014 Apr; 6(7):3742-52. PubMed ID: 24569711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
    He M; Zhao Z; Yin L; Tang C; Yin C
    Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.
    de la Fuente M; Seijo B; Alonso MJ
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):2016-24. PubMed ID: 18436835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines.
    Montagner IM; Banzato A; Zuccolotto G; Renier D; Campisi M; Bassi P; Zanovello P; Rosato A
    Urol Oncol; 2013 Oct; 31(7):1261-9. PubMed ID: 22341413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells.
    Lamontagne CA; Grandbois M
    Exp Cell Res; 2008 Jan; 314(2):227-36. PubMed ID: 17698062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.